Enlivex Receives Nasdaq Minimum Bid Price Non-Compliance Notice
ENLV is trading near its 52-week low of $0.66 (9.2% above the low).
Summary
Enlivex Ltd. has received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.
Key Events · Corporate Governance and Compliance · ENLV
-
Nasdaq Minimum Bid Price Non-Compliance
Enlivex received a notice from Nasdaq for failing to maintain a minimum bid price of $1.00 for 30 consecutive business days.
-
180-Day Compliance Period
The company has until November 9, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days.
-
Potential Delisting Risk
Failure to meet the requirement could lead to an additional compliance period (potentially requiring a reverse stock split) or, ultimately, delisting from Nasdaq.
Analysis · ENLV · Life Sciences
Enlivex has received a formal notice from Nasdaq indicating its ordinary shares have traded below the $1.00 minimum bid price for 30 consecutive business days. This triggers a 180-day compliance period, during which the company must maintain a closing bid price of at least $1.00 for 10 consecutive business days to avoid potential delisting. While there is no immediate impact on trading, failure to regain compliance could lead to a reverse stock split or, ultimately, delisting from Nasdaq.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.1M. The 52-week trading range was $0.66 to $2.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.